<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Calvin Poon on Medium]]></title>
        <description><![CDATA[Stories by Calvin Poon on Medium]]></description>
        <link>https://medium.com/@c4poon?source=rss-faa297872aa0------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*Zm8L5JyN2f6Loln9.</url>
            <title>Stories by Calvin Poon on Medium</title>
            <link>https://medium.com/@c4poon?source=rss-faa297872aa0------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 11:47:46 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@c4poon/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Benzodiazepines — A Tale of Two Sides]]></title>
            <link>https://medium.com/@c4poon/benzodiazepines-a-tale-of-two-sides-2c369a33a571?source=rss-faa297872aa0------2</link>
            <guid isPermaLink="false">https://medium.com/p/2c369a33a571</guid>
            <category><![CDATA[drugs]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[addiction]]></category>
            <category><![CDATA[benzodiazepines]]></category>
            <category><![CDATA[xanax]]></category>
            <dc:creator><![CDATA[Calvin Poon]]></dc:creator>
            <pubDate>Fri, 14 Aug 2020 18:40:25 GMT</pubDate>
            <atom:updated>2020-08-14T18:46:01.612Z</atom:updated>
            <content:encoded><![CDATA[<h3>Benzodiazepines — A Tale of Two Sides</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*yJcJK7F58dQi8oOT8Hie8Q.jpeg" /></figure><p>Benzodiazepines (e.g. lorazepam, temazepam, clonazepam) can be a challenging topic of discussion for patients and healthcare providers.</p><p>From a patient’s perspective, benzodiazepines are used for issues like anxiety, sleep, seizures, panic disorder, and alcohol. Benzodiazepines act on the GABA neurons in our brain to produce an overall “calming” effect.</p><p>From a healthcare provider’s perspective, these drugs are a quick fix for the conditions listed above but they do carry long-term side effects. Elderly patients are especially vulnerable to these long-term side effects because they have increased sensitivity and these drugs last longer in the body as elderly patients do not clear the drugs as readily as younger people. Some of these side effects include:</p><ul><li>5 times higher risk of memory and concentration problems</li><li>4 times higher risk of daytime fatigue</li><li>2 times higher risk in falls and fractures</li><li>2 times higher risk of a motor vehicle accident</li></ul><p>When we assess numerically the risk versus benefit, the picture becomes more unfavorable for benzodiazepines. Research from studies have shown that at the 2 weeks period for using benzodiazepines to help with sleep, 1 out of 13 patients find a benefit but 1 out of 6 patients were harmed by it.</p><p>Yet use of benzodiazepines are remains common.</p><p>As a pharmacist, this discussion is one that I have often with my patients. Often times, patients are not very clear on why they were started on this medication as it is part of their status quo of medications.</p><p>For healthcare providers, I would recommend the following:</p><ul><li>Set expectations upfront and that when patients are newly started on benzodiazepines, advise them there will be a reasonable attempt to taper this off once the acute issue has been managed.</li><li>Advise about the potential harmful effects.</li><li>For long-term users, this conversation will be more challenging. From my own practice though, many patients are open to switching to something else when I tell them about the potential harmful effects of benzodiazepines. It is also important to assess their state of mind (precontemplation, contemplation, preparation) and not force a change without engaging the patient.</li><li>Engage other healthcare providers as well because tapering off a benzodiazepines can take months.</li></ul><p>From a patient’s perspective, engage with your healthcare providers about the safety of long-term benzodiazepine use. There are certainly situations where the benefits of long-term use are acceptable and the risk may be worse. Often times for the condition it is being used to manage, there are safer alternatives that can be used.</p><p>Reference:</p><p>Centre for Effective Practice (CEP). Managing Benzodiazepine Use in Older Adults. 2019 June [cited 2020 August 14].</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2c369a33a571" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Perseverance]]></title>
            <link>https://medium.com/@c4poon/perseverance-d195bc2e7923?source=rss-faa297872aa0------2</link>
            <guid isPermaLink="false">https://medium.com/p/d195bc2e7923</guid>
            <category><![CDATA[children]]></category>
            <category><![CDATA[self-improvement]]></category>
            <category><![CDATA[motivation]]></category>
            <category><![CDATA[kids]]></category>
            <category><![CDATA[perseverance]]></category>
            <dc:creator><![CDATA[Calvin Poon]]></dc:creator>
            <pubDate>Thu, 13 Aug 2020 01:21:48 GMT</pubDate>
            <atom:updated>2020-08-13T01:21:48.868Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/715/1*GNhmkYjf-Orl0ytyPwc-mg.jpeg" /></figure><p>The race started. It was a 100m sprint. A tryout for the regional competition. The top two winners from my heat would move on to the regionals.</p><p>I feel really lucky to be on this starting line. Unlike the others, I was one grade below the rest of them and the only reason why I made it to the starting line was there were 2 spots missing and 2 selected runners from grade 3 can join. I was voted in along with one of my other classmates to represent our class because everybody felt we were the 2 fastest runners.</p><p>I wore the shoes my dad washed and prepared for me the night before. I’ve actually never ran on a gravel track before. I’m used to the grass while I play soccer or the pavement while we run towards the school door.</p><p>The race was short. I didn’t remember what happened. I ran as fast as I could and moved my legs harder than I ever did. I felt like a jet.</p><p>I don’t remember what place I came in. But I didn’t finish in the top 2. Neither did my classmate.</p><p>I lost. Frankly, I didn’t even know what “lost” meant. All I knew was I wasn’t going to the regionals.</p><p>I thought I was special but apparently not today.</p><p>Not special in grade 4 as well. I got a ribbon for participation in track and field.</p><p>Not special in grades 5, 6 or even 7. I came close a few times. The top 2 of each track and field event advance to the regionals. I came third once in 800m. I wished one of the top 2 finishers would get sick the day before the regionals so I can go because I was the backup.</p><p>I didn’t stop. I didn’t understand what lost meant. I just realized I wasn’t good enough.</p><p>My time came in grade 8. I went to the regionals that year and qualified for the provincial. I always knew I was special.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d195bc2e7923" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The History of Antidepressants and the Evolution of Depression]]></title>
            <link>https://medium.com/@c4poon/the-history-of-antidepressants-and-the-evolution-of-depression-8076373f31f8?source=rss-faa297872aa0------2</link>
            <guid isPermaLink="false">https://medium.com/p/8076373f31f8</guid>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[history]]></category>
            <category><![CDATA[evolution]]></category>
            <category><![CDATA[depression]]></category>
            <dc:creator><![CDATA[Calvin Poon]]></dc:creator>
            <pubDate>Sun, 04 Feb 2018 00:25:15 GMT</pubDate>
            <atom:updated>2018-02-04T00:25:15.490Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*KmHjj-7ujOJn2QXvvFTwEg.jpeg" /></figure><p>The intersection between the condition of depression and antidepressant medications is a complex interaction. The management of depression is unlike many other health conditions. On the one hand, you have this very complex depression state that you can’t exactly measure it objectively with one lab value, one objective reading, or one criterion. On the other hand, you have a highly specific (relatively) antidepressant medication that targets only a few specific chemical receptors in our body.</p><p>The discovery and evolution of antidepressants was truly a scientific marvel. From practically having no medications to reliably manage depression prior to the 1950s to a spectrum of medications nowadays to choose from, antidepressants evolved and progressed rapidly in the past 60 years. But has the introduction of antidepressants actually progressed the overall management of depression or was it actually a regression for medicine? In this article, I will briefly profile the scientific discovery, history, and evolution of antidepressants and then zoom out to assess whether this was a progression or regression.</p><h3>Discovery and Evolution of Antidepressants</h3><p>The discovery of antidepressants dates back to the 1950s and the discovery was actually blurred with the management of many other conditions (not even entirely psychiatric related).</p><p>In the late 1940s, French Navy surgeon Henri Laborit was in search of a cocktail to pre-medicate his patients to prevent surgical shock. He was looking for some kind of sedative effect that targetted an antihistamine effect (i.e. similar to the drowsy effect you get when you take Benadry® or diphenhydramine). In his efforts and along with other scientists, he came across a compound now known as chlorpromazine and provided remarkable calming and relaxing effect during the stressful pre-operative period.</p><p>Laborit, still trying to precisely determine the effects of chlorpromazine and its intended use, asked his psychiatric colleagues to test chlorpromazine on psychotic patients. In 1952, Joseph Hamon, the Director of the Neuropsychiatric Service at the Val-de-Grâce hospital tested the medication on a manic patient and at once, the patient became calm and remained so for a few hours. This was a scientific breakthrough as management of patients with psychiatry disorders was primarily managed by electroconvulsive therapy and use of medications was a novel idea.</p><p>At the same time period when scientists were exploring the calming and “tranquilizing” potential of chlorpromazine, Roland Kuhn of the Cantonal Psychiatric Clinic from Munsterlingen, Switzlerland, started testing the hypnotic effects of chlorpromazine and similar derivates. In particular, he came across a compound called G22150, or now better known as imipramine. In 1956, Kuhn administered imipramine to several patients with depression and noticed remarkable antidepressant effects. 7 months later, the astounding results were announced in the International Congress of Psychiatry held in Zurich and the explosion for the discovery of similar antidepressants began, namely with the discovery of trimipramine and clomipramine. Collectively, these medications belonged to a class called the tricyclic antidepressants.</p><p>During the 1960s, the various tricyclic antidepressants were classified based on whether they were sedating or stimulating. It was believed that these antidepressants primarily acted through enhancing norepinephrine activity but by the end of the decade, there was evidence emerging that part of its antidepressant effects may also be from enhancing the serotonin activity. The association between serotonin and its antidepressant effects were first proposed by Russians Izyaslav Laptin and Gregory Oxenkrug of Bekhterev’s Psychoneurological Research Institute in Leningrad. In 1969, they observed mood elevation when the brain was supplemented with serotonergic activity by tryptophan.</p><p>In the 1970s, pheniramine was the first medication to act primarily on serotonin to be tested for treatment of depression. It was marketed in Europe as zimelidine in 1982 but was withdrawn a few years later because of concerns about Guillain-Barré syndrome (progressive muscular weakness).</p><p>The next medication introduced that acted on serotonin was fluvoxamine. Compared to the tricyclic antidepressants, these serotonergic medications were much safer and had fewer side effects, especially during an intentional overdose. In 1988, Eli Lilly launched the commonly known fluoxetine (Prozac®).</p><p>Efficacy of Antidepressants</p><p>The word “antidepressant” denotes an antagonizing or opposing effect to the depressive condition. Ironically though, use of antidepressants are not as miraculous as you may think and the effects are not as black and white. It’s been reported that 34–46% of depression cases are termed as <em>treatment-resistant depression</em> despite the use of antidepressants. In the large clinical trial called the Sequenced Treatment Alternatives to Relieve Depression (STAR*D), a four-step treatment plan (including the use of antidepressants and cognitive behavioral therapy) was used to treat depressive patients. The results showed the cumulative remission rate (normalization of function) 67%; in another word, about two-thirds of patients reached remission but that also meant one-third of the patient was still in depressed.</p><p>I’m going to try to explore the management of depression from a more fundamental and grassroots perspective. Yes, the medications have shown remarkable results but if these medications are truly “anti” depression, wouldn’t you expect a higher level of success with treatment? Realizing that up to one-third of patients on these medications get no benefit is both puzzling and frustrating.</p><p>The current management of depression is trending towards better medications with fewer side effects but is this direction actually progressive medicine? I’m going to explore and play around with this topic and argue the discovery and evolution of antidepressant medication are actually <em>regressive </em>to our understanding and management of depression. Let’s trace back at some fundamentals.</p><h3>Evolution of Humans and Evolution of Depression</h3><p>The theory of natural selection by Charles Darwin suggests the evolution of humans has largely been shaped to optimize reproductive success and passing one’s genes onto the next generation. In humans, body features, cellular changes, and behaviors are selected based on its favourability for survival and reproduction. For example, in geographical areas with high rates of malaria, humans with the conditions sickle cell anemia are selected (i.e. favored) because the mutation of the red blood cells gives the people with sickle cell anemia protection against malaria.</p><p>Extending the idea of natural selection and that nature selects certain body conditions and behaviors to maximize survival and reproductive success, you may then wonder why is depression selected? Depression can be an extremely debilitating condition but then why has nature intentionally selected this condition to be passed along throughout our evolution? And then there is suicide. If natural selection is supposed to pick out conditions and behaviors that maximize survival and reproductive success, suicide is then the complete opposite but yet it seems nature has intentionally<em> </em>selected <em>for</em> depression and behaviors like suicide.</p><p>Evolutionary medicine can try to explain this discrepancy and why depression has persisted throughout human evolution. There are a few hypotheses.</p><p>Firstly, Freud coined the idea that depression is aggression turned inwards. Humans are constantly in competition with one another due to scarce resources and during these competitive times, there will be winners and losers. Depression may have been a behavioral mechanism to inhibit aggression which may have been more destructive.</p><p>A second hypothesis is that depression is a mechanism that helped our ancestors accept unobtainable goals. The ability to set goals and create ideas in our minds is one of the differentiating hallmark success of <em>Homo sapiens </em>from other animals. With ideation and goal setting though, will come disappointment and depression may be a method to cope with these disappointments and conserve energy.</p><p>A third hypothesis is an explanation and selection for postpartum depression. After child delivery, a woman with postpartum depression may be a plea for help from the woman’s partner or tribe members to help look after her and her child.</p><p>Lastly, there is the hypothesis that depression may be a “disease of modernity.” This idea is interesting in that it suggests our mind has not evolved to deal with our modern society; there is a discrepancy between the modern environment and the Savannian brain from our <em>Home sapien </em>ancestors. Modern society promotes a diet high in carbohydrate and sedentary lifestyle (i.e. low in exercise), which increases obesity rates and subsequently increases the risk of depression. The estimated daily energy expenditure of our hunter-gatherer ancestors was 3,000 kcal, a challenging target for the modern sedentary-oriented humans. LIght and sleep is also reduced in modern society as we spend more time indoors, both of which when deprived, are risk factors for depression. Lastly, increasing social competition places tremendous pressure on our minds and increases isolation. Our minds may simply not have yet evolved to adapt to these modern times.</p><p>There is much that remains in the dark when it comes to understanding depression and its management. Antidepressants, while helpful in some cases, is still not enough. Depression is a multifactorial condition with deep evolutionary connection and in order to properly manage this condition, multiple strategies and perspectives will be required.</p><p>What are your thoughts on this article? Please leave a comment below or share if you found something interesting and worth spreading.</p><h3>Reference</h3><p>Sneader, Walter. <em>Drug Discovery A History. </em>West Sussex: John Wiley &amp; Sons Ltd, 2005. Print.</p><p>Hillhouse TM. A brief history of the development of antidepressant drugs: From monoamines to glutamate. Exp Clin Psychopharmacol<a href="https://www.ncbi.nlm.nih.gov/pubmed/25643025#">.</a> 2015 Feb;23(1):1–21.</p><p>Hidaka BH. Depression as a disease of modernity: explanations for increasing prevalence. J Affect Disord. 2012 Nov;140(3):205–14.</p><p>Wolpert L. Depression in an evolutionary context. Philos Ethics Humanit Med. 2008 Feb 29;3:8.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8076373f31f8" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Why Successful Real Estate Investors Have No Tenants]]></title>
            <link>https://medium.com/@c4poon/why-successful-real-estate-investors-have-no-tenants-18ed24f97214?source=rss-faa297872aa0------2</link>
            <guid isPermaLink="false">https://medium.com/p/18ed24f97214</guid>
            <category><![CDATA[real-estate]]></category>
            <category><![CDATA[investing]]></category>
            <category><![CDATA[landlords]]></category>
            <category><![CDATA[finance]]></category>
            <category><![CDATA[money]]></category>
            <dc:creator><![CDATA[Calvin Poon]]></dc:creator>
            <pubDate>Tue, 28 Nov 2017 02:15:39 GMT</pubDate>
            <atom:updated>2017-11-28T02:15:39.138Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*_nUrwTwRGVcjXCZVTx0V-Q.jpeg" /></figure><p>Perhaps you are an amateur real estate investors with a few properties under your portfolios. You enjoy the financial aspect but the tenant experience is absolutely horrific. You are tired of dealing with tenant issues. For example, your tenants call you for tenant-to-tenant conflicts like being noisy or having too much guests. Or you have a tenant who calls you for the smallest thing like a squeaky door and unwilling to roll up their sleeves to do anything.</p><p>Let me tell you right now, if you are feeling fatigued from managing your tenant, perhaps its not the tenant, but it’s you.</p><p>The most successful real estate investors have no tenants — they have customers. I’d like to even stretch the term customers and call them residents.</p><p>Real estate is not just a business of land and housing, but there is also a very real human aspect to it as well — this is a person’s home, their most secure place in the world, or at least it should be if you are a decent landlord.</p><p>Here are 4 tips to change your perspective from seeing your tenants as tenants and seeing them as residents. Following these simple tip will save you those pesky phone calls and build you a better relationship with your residents.</p><ol><li>Heighten their positive experience</li></ol><p>I am giving full credit for this tip to an extremely successful investor <a href="http://mrhamilton.ca/">Erwin Szeto</a>, founder of the Mr. Hamilton Group and Halton Real Estate Investing Group.</p><p>Erwin used the analogy when we think about our experience at an amusement park, we remember only the very great and very awful experience. For example, we remember the very awful experience like the pricey food or the long wait times. But at the same token, we remember our incredible experience like the thrill of the roller coaster or seeing your kids having the highlight of their Summer. Even though a positive experience like a roller coaster ride is only a few minutes compared to the hours of wait time, we walk away with a positive experience because the positive experience was exponentially better than the wait times.</p><p>In real estate, we can do the same thing to heighten the positive experience. Maybe it is about sending your residents and their kids Christmas gifts to thank them. Or send them a gift card on their birthday or congratulating them when they graduate. A small gift or token of appreciation can really heighten somebody’s experience at home and also a nice surprise.</p><p>2. Invest in the smallest upkeep.</p><p>You are an investor, so look for ways where you can spend a little bit but protect your downside. During the springtime, buy your residents a plant nursery gift card to encourage some simple gardening. During the winter time, buy a shovel set to ensure they keep your driveway clean and so that nobody slips and fall, causing you to be on the hook for a lawsuit.</p><p>3. What would you want if you were living there?</p><p>Got some minor repairs and thinking whether you can simply let them live there ‘as is?’ Give it my litmus test, “what would you do if you were living there?” Imagine if you were living in the house and ask whether this is a problem that is livable or whether you need to fix it?</p><p>4. “I’ve learned that people will forget what you said, people will forget what you did, but people will never forget how you made them feel.” — Maya Angelou.</p><p>Place your residents’ feelings as a priority. Ensure they feel safe. Ensure they feel secured and comfortable talking to you. You are the landlord so you may obviously be in a position of power, be aware of that but don’t abuse that to create a negative feeling.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=18ed24f97214" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Choices in Healthcare Part 2 — Problems with Having a Choice in Healthcare]]></title>
            <link>https://medium.com/@c4poon/choices-in-healthcare-part-2-problems-with-having-a-choice-in-healthcare-3f1ee3533cf9?source=rss-faa297872aa0------2</link>
            <guid isPermaLink="false">https://medium.com/p/3f1ee3533cf9</guid>
            <category><![CDATA[lifestyle]]></category>
            <category><![CDATA[decision-making]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[choices]]></category>
            <category><![CDATA[freedom]]></category>
            <dc:creator><![CDATA[Calvin Poon]]></dc:creator>
            <pubDate>Thu, 09 Nov 2017 23:13:44 GMT</pubDate>
            <atom:updated>2017-11-09T23:13:44.226Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*AsVFf1TSSOXPekQhReGD9A.jpeg" /></figure><p>In the <a href="http://www.redandwhitepill.com/healthcare-choices-part-1/#more-247">first</a> part of this 2 part series, we explored reasons why having a choice in healthcare is encouraged. There may be situations where paradoxically, having a choice by patients can create problems and be in direct conflict with a patient’s own best interest. We use the terminology patient-centered care in healthcare where patients are at the center of decision making and their wishes and values are respected without judgement. But is patient-centered care the same as patient freely deciding on the course of their care. There may be some situations where patients are set up to decide but the position they are in will ultimately not serve their <em>own </em>best interest. In this second part, we explore some of the situations where having a choice can create new and unintentional problems. Again, much of what I will be discussing in this article came from the writings of Thomas Rice.</p><h3>Problems with Having a Choice</h3><p><strong>1) When a patient does not know which choices will make him or her better off</strong></p><p>While having a choice positions a patient to be engaged in their own path, there may be situations where patients deciding may actually not be in the best interest of themselves. An example of this situation is with drug abuse, where the need of a drug for recreational purpose as chosen by a consumer is actually not in the best interest of their long-term health.</p><p>Tibor Scitovsky (1976) gives a great example of how when you are unaware of your own best interest, having the ability to decide may simply be putting you in a challenging situation:</p><p><em>The economist’s traditional picture of the economy resembles nothing so much as a Chinese restaurant with its long menu. Customers choose from what is on the menu and are assumed always to have chosen what most pleases them. That assumption is unrealistic, not only of the economy, but of Chinese restaurants. Most of us are unfamiliar with nine-tenths of the entrees list; we seem invariably to order either the wrong dishes or the same old ones. Only on occasions when an expert does the ordering do we realize how badly we do on our own and what good things we miss.</em></p><p><strong>2) During complex decision points when a patient cannot process the information about the various choices and consequences</strong></p><p>Consider healthcare insurance and looking for the right policy; the medical jargon is immensely complicated and unless you have the knowledge in this field, patients can be placed in a really challenging situation if they don’t fully understand the consequences and the financial structures.</p><p><strong>3) When patients don’t actually want to have a choice</strong></p><p>Having a choice for some patients may actually not be encouraged in some situations as it may induce subsequent regrets. Richard Thaler (1991) writes, “Whenever choice can induce regret consumers have an incentive to eliminate the choice. They will do so whenever the expected increase in pleasure derived from making their choices is less than the expected psychic costs which the choices will induce.” Consider the example in a theme park where one pays a flat entrance fee and have access to all rides verus individual cost for each ride separately; if it was the latter, one may express regrets when deciding which rides to choose and which ride to bypass.</p><h3>Summary</h3><p>To summarize this 2 part series, as you can see, choices has a double edge; on the one side, it enables and engages patients in their healthcare selection but on the other side, healthcare is a complex matter and patients may not always have the necessary knowledge to comprehend the consequences and may paradoxically <em>not </em>want to have a choice. This pivot and crossroad point is very relevant for complex decisions such as somebody deciding on matters like health insurance (should one even get insurance, what kind of insurance, and what kinds of benefits), selecting hospitals, or therapy junctures and weighting the benefits versus potential side effects.</p><p>I believe patient-centered care remains a core model we need to be striving towards. When patients have to make a decision, we need to be provided the adequate resources and support to make an informed decision.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3f1ee3533cf9" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Choices in Healthcare Part 1- Why Having a Choice in Healthcare is Encouraged]]></title>
            <link>https://medium.com/@c4poon/choices-in-healthcare-part-1-why-having-a-choice-in-healthcare-is-encouraged-6eba933d8a5b?source=rss-faa297872aa0------2</link>
            <guid isPermaLink="false">https://medium.com/p/6eba933d8a5b</guid>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[freedom]]></category>
            <category><![CDATA[lifestyle]]></category>
            <category><![CDATA[choices]]></category>
            <category><![CDATA[medicine]]></category>
            <dc:creator><![CDATA[Calvin Poon]]></dc:creator>
            <pubDate>Sun, 05 Nov 2017 23:55:41 GMT</pubDate>
            <atom:updated>2017-11-05T23:55:41.836Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*aE_mVuFRg3AVz4Y_5f6ogQ.jpeg" /></figure><p>Patient-centered care is a term that is bounced a fair amount in the healthcare sector but what does that actually mean? Whether you are a healthcare provider, a patient, or a family member, we all have the same desired outcome — the best for the patient. The provision of healthcare, however, is complex with various forces in play — healthcare culture, relationship with providers, patient values, finance, and etc. The binding substance across all these various forces at play is <strong>choice and decision making</strong>. But is patient-centered care the same as patient deciding? Does having a choice lead to better health outcomes? In this 2 part series, I am going to be exploring the pro and con side of patients having a choice. In this first series, I will be discussing why having a choice by patients are encouraged and in the next part, I will be looking at the paradoxical viewpoint where patients having a choice doesn’t actually serve the best outcome. I will be basing much of my discussion points from the writings of Thomas Rice.</p><h3>Patients Having A Choice</h3><p>Our society is ever reliant on providing choices to consumers. For example, more colors of iPhone to choose from, more styles of jeans (skinny, tight, straight), more options with the menu, and etc. Ask your parents or grandparents and you’d be surprised by the limited choices they had in their days. Choices are everywhere.</p><p>The same can be said in healthcare and patients making their own choice are encouraged. There are two main reasons why pro-choice in healthcare has been a progressive movement:</p><p><strong>1) We enjoy our goods and services more when we choose them</strong></p><p>With medications, empowering and engaging patients can be one of the most challenging tasks. When patients feel they do not have a choice or feel obligated to take a medication, it is a burden and results in low adherence. In contrast, when patients are given a choice and decide on their medication regimen, they effectively become drivers of their own healthcare and are more likely to adhere to the regimen.</p><p><strong>2) Choices breeds competition in the market and thereby the competitive nature leads to lower prices and product differentiation</strong></p><p>Think about blood sugar testing meters or blood pressure monitors. There are a variety of options to choose from and manufacturers are forced to continually refine their product or create a better offering to keep up with the competition. This has been healthy for the market as patients are given a variety of options and price points to choose from. When there is competition in the market, we will ultimately be given better products and services and in healthcare, this fuels the drive to push towards more innovation and reasonable prices.</p><p>In part 2 of this series, I will be looking at perhaps why having a choice is paradoxically not in the best interest of patient-centered care, stay tuned as this should be a good one.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6eba933d8a5b" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Does Vitamin D Supplementation Give an Unfair Advantage for Strength Training]]></title>
            <link>https://medium.com/@c4poon/does-vitamin-d-supplementation-give-an-unfair-advantage-for-strength-training-4b00674da4bb?source=rss-faa297872aa0------2</link>
            <guid isPermaLink="false">https://medium.com/p/4b00674da4bb</guid>
            <category><![CDATA[vitamin]]></category>
            <category><![CDATA[fitness]]></category>
            <category><![CDATA[gym]]></category>
            <category><![CDATA[crossfit]]></category>
            <category><![CDATA[workout]]></category>
            <dc:creator><![CDATA[Calvin Poon]]></dc:creator>
            <pubDate>Fri, 03 Nov 2017 02:19:56 GMT</pubDate>
            <atom:updated>2017-11-03T02:19:56.978Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Bn2BO8csH1ts8_3yq6DZaQ.jpeg" /></figure><p>If you are into powerlifting, weightlifter, or generally looking to improve your gains and strength training, you need to read this.</p><p>While performance-enhancing drugs like anabolic steroids are strictly prohibited and enlisted on the <a href="http://www.wada-ama.org/sites/default/files/prohibited_list_2018_en.pdf">World Anti-doping Code International Standard</a>, vitamin D is not a prohibited substance and there are actually some suggestions that it leads to <a href="https://www.bodybuilding.com/fun/d-up-the-case-for-vitamin-d.html">strength gain</a>. In this article, I will explore the science behind vitamin D and the potential associated strength gain and muscle growth. I will be basing much of my evidence and scientific findings from the Chiang et al study from 2016.</p><h3>Physiology</h3><p>You may think vitamin D is for bones only and how does vitamin D even remotely help with muscle growth and strength gains? Firstly, check out my other <a href="http://www.redandwhitepill.com/vitamin-d-falls/">post</a> that talks about how vitamin D helps with falls prevention. While we are still not entirely certain about the physiology, vitamin D does have some roles in muscle growth:</p><ul><li>Vitamin D has been estimated to help regulate over 1,000 gene expression in our body, accumulating to 5% of the entire protein-coding genome; through a complex interaction of the mitogen-activated protein kinase (MAPK), vitamin D helps with muscle cell growth and proliferation</li><li>Calcium is required for proper muscle contraction and vitamin D has an instrumental role in regulating the uptake of calcium into our muscle fibers</li><li>Vitamin D receptors are found all over our heart and body muscles and postulated to help with proper oxygenation of the muscle fibers</li></ul><h3>Does Vitamin D Supplementation Lead to Gains in the Gym</h3><p>So the physiology is a bit washy and if you are a lifter, you probably don’t care much about that unless there is proof that it can add weights to your lifts. I will be basing much of my evidence from the systematic review by Chiang et al from 2017. In this review, the investigators looked at whether giving vitamin D supplements resulted in muscle strength gain. Let’s take a closer look.</p><p>Of the 6 studies that looked at vitamin D supplementation, 2 showed a statistically significant gain in strength, 2 were close but not close enough to show a statistically significant gain, and 2 did not show any difference.</p><p>Of the 2 studies that showed vitamin D was effective, the investigators compared vitamin D3 at a dose of 4000 units or 2000 units daily versus placebo. These studies were carried over either 35 days or 4 months. The results demonstrated gains with regards to quadriceps contraction and percentage of maximal leg press weight after a strenuous exercise. Although these were statistically significant findings, I honestly didn’t find the outcomes studied very meaningful. In powerlifting at least, does this translate to a bigger bench or a heavier squat or deadlift? This question is unanswered despite the positive results.</p><p>The next 2 studies that showed close results did, in fact, measure important outcomes like the bench, squat and leg press. These studies gave the participants vitamin D3. The participants who took vitamin D used anywhere from 5000 units to 40,000 units per week (which are clinically quite massive doses). Although the results did not reach statistical significance, it did, however, showed a positive trend; in one study, participants who took vitamin D were able to bench 6.5kg more than their baseline versus those who were not taking vitamin D only saw a 2.5kg gain. Similarly, those who took vitamin D saw their squats improve by 9.0kg at the end of the study versus 3.0kg in those who did not take it. There are however some conflicting results from the second study. In this second study, participants who took vitamin D saw improvements in their bench and leg press when compared with their counterparts who didn’t (similar to the first study). The inconsistent fact is that in the control group, those who performed the bench and leg press paradoxically did worse in the end; their maximal bench went down by -7.67kg and leg press -14.33kg. This is very unusual and may highlight some design flaws as you would expect the control would still make gains, but just not as much compared to the vitamin D group if indeed vitamin D does have some effect on strength gains.</p><p>In the last 2 studies, there were no improvements with vitamin D supplementation with regards to strength gains. It is interesting to note these 2 studies used vitamin D2, another form of vitamin D that comes primarily from our diet.</p><p>So does vitamin D give an unfair advantage to strength athletes? The answer remains inconclusive as the results showed mixed outcomes. While there is some evidence suggesting that it may be associated with strength gains, this may not directly translate to a bigger bench or heavier squat/deadlift. We are also not aware of any potential side effects.</p><p>Best gains are still the gains you make by diligently going to the gym and working out on a consistent basis.</p><p>Reference</p><p>Chiang CM, Ismaeel A, Griffis RB, Weems S. Effects of Vitamin D Supplementation on Muscle Strength in Athletes: A Systematic Review. J Strength Cond Res. 2017;31(2):566–574.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=4b00674da4bb" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Bernie Sanders vs Healthcare — Why You Can’t Serve French Cuisine in an Italian Restaurant]]></title>
            <link>https://medium.com/@c4poon/bernie-sanders-vs-healthcare-why-you-cant-serve-french-cuisine-in-an-italian-restaurant-5ef970f8bcd6?source=rss-faa297872aa0------2</link>
            <guid isPermaLink="false">https://medium.com/p/5ef970f8bcd6</guid>
            <category><![CDATA[bernie-sanders]]></category>
            <category><![CDATA[democrats]]></category>
            <category><![CDATA[trump]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[Calvin Poon]]></dc:creator>
            <pubDate>Mon, 30 Oct 2017 21:11:59 GMT</pubDate>
            <atom:updated>2017-10-30T21:11:59.821Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/630/1*AyXJn7WXWWOS9PUcUE5ZSQ.jpeg" /><figcaption>JAY LAPRETE/GETTY IMAGES — Sen. Bernie Sanders (I-Vt.), who hit the road over the summer to defend the Affordable Care Act, is set to introduce legislation Wednesday to create a single-payer health care system.</figcaption></figure><p>Bernie Sanders proposed a new healthcare vision to have a <a href="http://www.huffingtonpost.ca/entry/bernie-sanders-single-payer-bill-major-support-senate_us_59b87dc1e4b02da0e13d465f">single-payer healthcare system</a>. The single payer will effectively be a government-operated insurance program for all Americans.</p><p><a href="http://www.huffingtonpost.ca/2017/10/29/kathleen-wynne-takes-bernie-sanders-on-hospital-tour-to-show-off-canadian-healthcare_a_23259823/?ncid=fcbklnkcahpmg00000001">Bernie Sanders visited Premier of Ontario, Kathleen Wynne</a> and examined first hand what a comparator model of this single-payer healthcare system looks like. I think Ontario would be a close comparator.</p><h3>What Does Healthcare Look Like in Ontario, Canada</h3><p>I live in Ontario and I can try to provide a background of what this single-payer (government-operated) healthcare system looks like. For starters, visiting your family doctor, a walk-in, or a visit to the hospital will not cost you anything from your wallet. If you need prescription medications, there are special social programs for those in need or seniors to cover the cost of the drugs. Lab and diagnostic tests and images are <em>mostly </em>covered. For <em>most </em>allied health services (e.g. outpatient physiotherapy), there are no programs that provide direct coverage. Dental services, unless performed in a hospital, are not covered.</p><h3>Why Bernie Sander’s Vision Will Not . . . Click Smoothly</h3><p>I can’t say with certainty that Bernis Sander’s vision of a single-payer healthcare system won’t, “work,” because to say something works or doesn’t work is very extreme. Rather, I think the gears will click but it will be very choppy and likely miss a few clicks.</p><p>While I have no objection to this vision, I think there is a fundamental gap between the vision of a single-payer and multiple social forces that shape how services and care are provided. It is kind of like you are trying to serve dinner and there is a preference for various cuisines (e.g. French, Italian, Chinese, and Japanese) — at the end of the day, food will be put on the table but the clash between various cuisines and food preferences will tear apart the dinner experience. Here are these 4 forces in conflict:</p><p><strong>1) Ethics</strong></p><p>Healthcare is a finite and scarce resource. There are only so many beds in a hospital and so many dollars allocated for coverage of drugs. How can a single-payer system fairly allocate these resources in an ethical way?</p><p><strong>2) Economics</strong></p><p>How will the single-payer system be funded? Here in Ontario, we have high taxes and partly this is to cover the cost of running this behemoth system. Claiming a single-payer system is noble but where is the money coming from?</p><p><strong>3) Clinical</strong></p><p>Healthcare is not a one size fit all and there are regional differences and differences in the practice based on the clinician. How do we ensure the practices are standardized and that there are no biases in the clinical outcomes?</p><p>I don’t think you can truly equalize every practice and differences will exist as there is a very human component to healthcare; regression towards to mean should provide us a fair capture of the overall clinical outcomes. But with a single-payer system, how do we ensure there are minimal variations above or below this mean?</p><p><strong>4) Patient and media</strong></p><p>Clinicians must seal their lips to protect patient confidentiality and cannot start leveraging the media to their advantage. On the other hand, patients have infinite access and control over the media and the media can have a huge influence on the overall population perspective. How can we balance the power of clinicians and patients/media?</p><p>The content in this article solely represents my points and opinion. I don’t claim to be an expert in this field and this is a much more complex topic than the few paragraphs we listed above.</p><p>If you like this discussion, comment and/or share this article. Awareness and attention is the currency for making change happen in healthcare.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=5ef970f8bcd6" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What Healthcare Can Learn from SpaceX]]></title>
            <link>https://medium.com/@c4poon/what-healthcare-can-learn-from-spacex-550813afd324?source=rss-faa297872aa0------2</link>
            <guid isPermaLink="false">https://medium.com/p/550813afd324</guid>
            <category><![CDATA[innovation]]></category>
            <category><![CDATA[ideas]]></category>
            <category><![CDATA[trump]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[Calvin Poon]]></dc:creator>
            <pubDate>Wed, 25 Oct 2017 23:58:04 GMT</pubDate>
            <atom:updated>2017-10-27T06:17:14.804Z</atom:updated>
            <content:encoded><![CDATA[<p>SpaceX didn’t reinvent rocket science or did they found a faster way to get into space, but they made one remarkable leap jump — they made rocket reusable. The geniuses at SpaceX realized it wasn’t that rocket science stagnated since NASA landed on the moon half a century ago, but it was too expensive to fly into space. Specifically, everytime a rocket was launched, the majority of the components were wasted. SpaceX approached the problem from a different angle — if it was the cost that was prohibiting rocket science, what if there was a way to reduce the costs? When the problem was approached with this question, the answer became clear — reusable rockets.</p><h3>Medication Wastage</h3><p>Medication wastage is a huge problem in the healthcare industry. For example, when a patient goes into the hospital, the hospital makes an attempt to supply the patient with their required medical needs (e.g. bed, clothing, diagnostic scans, and medications). Bed and clothing items can be reused after it has been properly washed. Diagnostic equipment like ultrasound can be properly cleaned and sterilized after patient use. But medication is different in that you can’t really share wasted medication.</p><p>Medication wastage in the hospital pertains to items such as IV vials or devices. For example, if a patient requires a medication that is IV and the vial is a one-time use, you can’t really save this IV vial for a later date (it’s not like leftover food) — the sterility and stability of the medication will be compromised. Perhaps this is the cost of doing business. One could argue IV vials should be made smaller and this is a fair point.</p><h3>Wasted Medication Devices</h3><p>I’d like to focus on the device medications, such as a puffer and insulin pen. I’m not trying to pick on any brand specifically but my examples that follow are simply to demonstrate my point.</p><p>If a patient came into the hospital and required a puffer called Symbicort®, it will cost the hospital around $87. Symbicort® has 200 doses but if the patient only stayed for a few days and used a few doses, we as a system effectively flushed around $80 into the garbage bin. Another example would be insulin, such as Lantus®. One Lantus® pen is about $20 and the pen has 300 units. During the course of a hospital stay, if a patient required only half the contents of the pen, the remaining 150 units or $10 would be wasted. $10 from the wasted Lantus® doesn’t sound much but very likely, virtually all patients would not require exactly 300 units of Lantus® the day they are discharged so there will certainly be wastage. You factor this across the hundred or thousands of patients on Lantus® and this becomes a significant tab to pick up. You can also extrapolate this issue to virtually all the other insulin pens.</p><p>I personally think a smaller and more flexible size of the medications would be a simple and game changer to save money for the system. Symbicort®, for example, contains 200 doses per puffer but what if there was a smaller size that only offers say 50 doses. Lantus® has 300 units per pre-filled pen but what if there was a pen that only has 100 units. We would still not be able to eliminate the medication wastage but by providing a smaller denomination dose amount, we could be more flexible and economic with the amount we waste. Many of the medications pack size are made for chronic and home use but during the course of a hospital stay, a miniature size would be much more cost-effective.</p><p>Check out this video from Vox that essentially advocates for the same point.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=550813afd324" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Effects of Vitamin A and E on Healthy Heart]]></title>
            <link>https://medium.com/@c4poon/the-effects-of-vitamin-a-and-e-on-healthy-heart-9afe995e6259?source=rss-faa297872aa0------2</link>
            <guid isPermaLink="false">https://medium.com/p/9afe995e6259</guid>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[vitamins-and-supplements]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[heart]]></category>
            <dc:creator><![CDATA[Calvin Poon]]></dc:creator>
            <pubDate>Tue, 24 Oct 2017 00:26:24 GMT</pubDate>
            <atom:updated>2017-10-24T00:26:24.145Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*m5igG4kQbspT3yyHfEUHCw.jpeg" /></figure><p>Vitamins are everywhere! You can get most of them without a prescription and over-the-counter at the pharmacy. But does this mean these vitamins are effective? What about safety; you probably presumed if it is available as over-the-counter, there shouldn’t be any safety concerns with these, right? In this article, I’m going to take a closer look at 2 of the most common vitamins, vitamin A and vitamin E and the evidence for use against heart disease.</p><p>I will be basing much of my literature from a meta-analysis done back in <a href="https://www.ncbi.nlm.nih.gov/pubmed/12814711">2003 by Vivekananthan and colleagues</a>.</p><h3>Physiology</h3><p>Let us first explore the physiology behind vitamins and heart disease protection and whether there is any logic behind to begin. It is believed and known that heart disease is caused by blockage of our arteries by cholesterol through an inflammatory pathway. Vitamins such as vitamin A or vitamin E are known to have anti-oxidant effects that neutralize this inflammatory pathway and helps in preventing heart disease. So far so good right, this all seems to make sense. Let’s now take a look at some real, clinical evidence.</p><h3>Vitamin A</h3><p>In the article by <a href="https://www.ncbi.nlm.nih.gov/pubmed/12814711">Vivekananthan and colleagues</a>, this was a meta-analysis looking at the efficacy of vitamin A by combining many different trials. The meta-analysis compared the heart-protective effects of vitamin A (beta-carotene) versus those who were not taking it. I think overall, the meta-analysis was done quite well and included only trials that had 1000 patients or more to prevent the data being skewed by smaller and potentially less valid trials. The meta-analysis for vitamin A, in the end, had 138 113 patients in the end, which is a very large sample size.</p><p>The results were surprisingly stunning and can be summarized by the following forest plot:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/657/0*7wv-EQyfjahcC-LX.jpg" /></figure><p>Forest Plot of Death (from any cause) between Vitamin A vs Placebo</p><p>For those who are unfamiliar with forest plots, the bottom from this meta-analysis was that those who took vitamin A (beta-carotene), actually had a <em>higher </em>risk of death (from any cause). Similar results demonstrating negative outcomes with vitamin A was seen when we look specifically at death from heart disease — those who took vitamin A had a higher association with death from heart disease versus those who are not taking it.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/668/0*07I4_Q7E20s9wMeT.jpg" /></figure><p>Forest Plot of Death (from heart disease) between Vitamin A vs Placebo</p><p>It is very important to interpret this carefully and not to jump to false conclusions here. The data shows there is a statistically significant association with death and those taking vitamin A but whether vitamin A actually <em>cause</em> more death remains uncertain. An association does not lead to causation and there can be many factors influencing these trials because it is not one trial but rather, a combination of many trials. One fact though is that taking vitamin A does not suggest a heart-protective effect.</p><h3>Vitamin E</h3><p>Similar to vitamin A, vitamin E can have powerful anti-oxidative effects and this is hypothesized to help reduce blockage of heart blood vessels and potentially lead to lower. The meta-analysis included 81 788 patients to compare the effects of vitamin E versus placebo. The results were less clear and vitamin E did not seem to offer either a protective effect or potential for harm due to death from any cause.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/653/0*qqhxPm6urDpp-dEl.jpg" /></figure><p>Forest Plot of Death (from any cause) between Vitamin E vs Placebo</p><p>The uncertainty benefit or harm from vitamin E was also seen when the investigators looked at death specifically from heart disease.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/651/0*33HtoMPm5DmoZruT.jpg" /></figure><p>Forest Plot of Death (from heart disease) between Vitamin E vs Placebo</p><h3>Take Home Message</h3><p>The take-home message here is that the heart-protective effects of vitamin A and vitamin E are not as black and white as you may think. Those who take vitamin A, there actually seems to be suggestions that it may actually be harmful. Vitamin E remains unclear whether it is harmful or beneficial. Be informed about these vitamins, do your research, ask your healthcare providers and make an informed decision.</p><p>If you like this article, please give it your thumbs up. If you want to see more articles like this, please comment below. Thank you for your support.</p><p>Reference</p><p>Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet<a href="https://www.ncbi.nlm.nih.gov/pubmed/12814711#">.</a> 2003;361(9374):2017–23.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=9afe995e6259" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>